CN1674941A - 固体纳米药物及其制备方法 - Google Patents
固体纳米药物及其制备方法 Download PDFInfo
- Publication number
- CN1674941A CN1674941A CNA038188139A CN03818813A CN1674941A CN 1674941 A CN1674941 A CN 1674941A CN A038188139 A CNA038188139 A CN A038188139A CN 03818813 A CN03818813 A CN 03818813A CN 1674941 A CN1674941 A CN 1674941A
- Authority
- CN
- China
- Prior art keywords
- medicine
- preparation
- parents
- complex
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 权利要求书1、 一种固体纳米药物的制备方法, 包括:A.提供含有双亲物质的溶液;B.将药物加入所述双亲物质的溶液中;C.形成药物与双亲物质的配合物; 和D.减压浓縮使配合物转变为固体颗粒。2、根据权利要求 1所述的制备方法,其中所述双亲物质选自羟丙基倍他环糊精、 磷脂或它们的组合。3、根据权利要求 1所述的制备方法,其中溶解所述双亲物质的溶剂选自亲水性 有机溶剂、 水或它们的组合。4、根据权利要求 2所述的制备方法,其中所述双亲物质为羟丙基倍他环糊精和 磷脂, 其质量比为 1:0.05〜0.3。5、 根据权利要求 1所述的制备方法, 其中溶解所述双亲物质是在 30〜100°C下 进行。6、根据权利要求 5所述的制备方法,其中溶解所述双亲物质是在 60〜75°C下进 行。7、 根据权利要求 1所述的制备方法, 其中所述药物选自: 紫杉醇; 蒿甲醚; 双 氢青蒿素; 白消安; 尼莫地平; 尼群地平; 硝苯地平; 地西泮; 桂利嗪; 洛伐他汀; 以及辛伐他汀的至少一种。8、根据权利要求 1所述的制备方法,其中所述药物与所述双亲物质形成的配合 物的颗粒直径在 300nm以下, 外围是双亲物质, 内部是药物。9、 根据权利要求 1和 7中任一项所述的制备方法, 其中可以进一步使用稳定剂 和表面活性剂。10、 根据权利要求 9所述的制备方法, 其中所述表面活性剂为聚山梨酯 80。 11、 根据权利要求 10所述的制备方法, 其中所述稳定剂选自聚维酮 K3o或 K1: (PVP) 和右旋糖酐 40、 70。12、 根据权利要求 1至 11任一项所述的制备方法制备的固体纳米药物。13、 根据权利要求 12所述的固体纳米药物, 其中所述药物为紫杉醇。14、 根据权利要求 12或 13所述的固体纳米药物, 其特征在于可用于静脉输注, 腹腔注射, 雾化吸入或口服治疗。15、 一种用权利要求 12所述的固体纳米药物配制的注射液。16、 根据权利要求 15所述的注射液, 其中所述药物为紫杉醇。17、 一种药物配合物的制备方法, 该方法包括:Α.提供含有双亲物质的溶液;Β.将药物加入所述双亲物质的溶液中; 和C.形成药物与双亲物质的配合物。18、 根据权利要求 17所述的药物配合物的制备方法, 其特征在于:还包括将所述配合物减压浓缩制备为无菌固体颗粒的工序。19、根据权利要求 17或 18所述的制备方法,其中所述双亲物质选自羟丙基倍他 环糊精、 磷脂或它们的组合。20、根据权利要求 17所述的制备方法,其中溶解所述双亲物质的溶剂选自亲水 性有机溶剂、 水或它们的组合。21、 根据权利要求 1所述的制备方法, 其中所述药物选自: 紫杉醇; 蒿甲醚; 双氢青蒿素; 白消安; 尼莫地平; 尼群地平; 硝苯地平; 地西泮; 桂利嗪; 洛伐他 汀; 以及辛伐他汀的至少一种。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021288453A CN100479807C (zh) | 2002-08-15 | 2002-08-15 | 药物输送系统——固体纳米药物的制备方法 |
CN02128845.3 | 2002-08-15 | ||
CN02149146.1 | 2002-11-25 | ||
CNA021491461A CN1502332A (zh) | 2002-11-25 | 2002-11-25 | 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1674941A true CN1674941A (zh) | 2005-09-28 |
CN100518831C CN100518831C (zh) | 2009-07-29 |
Family
ID=31979238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038188139A Expired - Fee Related CN100518831C (zh) | 2002-08-15 | 2003-08-13 | 固体纳米药物及其制备方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050255164A1 (zh) |
EP (1) | EP1543841A4 (zh) |
JP (1) | JP2006500387A (zh) |
KR (1) | KR20060021278A (zh) |
CN (1) | CN100518831C (zh) |
AU (1) | AU2003257791A1 (zh) |
CA (1) | CA2495899A1 (zh) |
HK (1) | HK1083749A1 (zh) |
WO (1) | WO2004022100A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4884975B2 (ja) * | 2004-10-01 | 2012-02-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 微粒子含有組成物およびその製造方法 |
BRPI0619938A2 (pt) * | 2005-12-16 | 2011-10-25 | Univ Kansas | nano agrupamentos para envio de terapêuticos |
KR100917809B1 (ko) * | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
WO2007142440A1 (en) * | 2006-06-02 | 2007-12-13 | Sk Chemicals Co., Ltd. | Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same |
CN101511348B (zh) * | 2006-08-30 | 2012-04-18 | 国立大学法人九州大学 | 含有包封他汀类之纳米颗粒的药物组合物 |
GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
EP1952803A1 (en) | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
CN101702878B (zh) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
KR101502533B1 (ko) * | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
KR20140006879A (ko) | 2011-02-17 | 2014-01-16 | 에프. 호프만-라 로슈 아게 | 고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법 |
US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
MX2015008911A (es) | 2013-01-22 | 2015-10-22 | Hoffmann La Roche | Composicion farmaceutica con biodisponibilidad mejorada. |
CN104013601A (zh) * | 2014-06-06 | 2014-09-03 | 重庆医科大学 | 姜黄色素羟丙环糊精磷脂纳米粒及其制备方法 |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
CN106092861B (zh) * | 2016-05-26 | 2019-02-26 | 国家纳米科学中心 | 用于纳米颗粒的光谱椭偏拟合方法 |
CN107952064B (zh) * | 2016-10-14 | 2023-10-20 | 江苏豪森药业集团有限公司 | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 |
KR20190141244A (ko) | 2017-05-03 | 2019-12-23 | 사이덱스 파마슈티칼스, 인크. | 사이클로덱스트린 및 부설판을 함유하는 조성물 |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59216820A (ja) * | 1983-05-20 | 1984-12-06 | Taisho Pharmaceut Co Ltd | プロスタグランジン脂肪乳剤 |
US4950432A (en) * | 1987-10-16 | 1990-08-21 | Board Of Regents, The University Of Texas System | Polyene microlide pre-liposomal powders |
DK49791D0 (da) * | 1991-03-20 | 1991-03-20 | Novo Nordisk As | Nasalt pulverpraeparat |
DE4140185C2 (de) * | 1991-12-05 | 1996-02-01 | Alfatec Pharma Gmbh | Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
DK0695169T3 (da) * | 1993-04-22 | 2003-03-17 | Skyepharma Inc | Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse |
WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
WO1995032737A1 (en) * | 1994-05-27 | 1995-12-07 | Farmarc Nederland Bv | Pharmaceutical composition |
US5902604A (en) * | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
HUP9701945A3 (en) * | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
FR2775435B1 (fr) * | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
WO1999066635A1 (en) * | 1998-06-16 | 1999-12-23 | Microwave Solutions Limited | Oscillator circuit |
FR2792942B1 (fr) * | 1999-04-29 | 2001-06-08 | Commissariat Energie Atomique | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes |
EP1259225B1 (en) * | 2000-02-04 | 2006-10-04 | Lipoxen Technologies Limited | Process of dehydration/rehydration for making liposomes |
CN1165305C (zh) * | 2002-12-13 | 2004-09-08 | 北京东方天翔医药技术开发有限公司 | 尼莫地平冻干组合物 |
-
2003
- 2003-08-13 CA CA002495899A patent/CA2495899A1/en not_active Abandoned
- 2003-08-13 CN CNB038188139A patent/CN100518831C/zh not_active Expired - Fee Related
- 2003-08-13 EP EP03793565A patent/EP1543841A4/en not_active Withdrawn
- 2003-08-13 JP JP2004533170A patent/JP2006500387A/ja active Pending
- 2003-08-13 US US10/524,808 patent/US20050255164A1/en not_active Abandoned
- 2003-08-13 KR KR1020057002588A patent/KR20060021278A/ko not_active Application Discontinuation
- 2003-08-13 AU AU2003257791A patent/AU2003257791A1/en not_active Abandoned
- 2003-08-13 WO PCT/CN2003/000663 patent/WO2004022100A1/zh active Application Filing
-
2006
- 2006-03-27 HK HK06103801.7A patent/HK1083749A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1543841A1 (en) | 2005-06-22 |
AU2003257791A1 (en) | 2004-03-29 |
KR20060021278A (ko) | 2006-03-07 |
WO2004022100A1 (fr) | 2004-03-18 |
EP1543841A4 (en) | 2011-03-16 |
CA2495899A1 (en) | 2004-03-18 |
JP2006500387A (ja) | 2006-01-05 |
US20050255164A1 (en) | 2005-11-17 |
CN100518831C (zh) | 2009-07-29 |
HK1083749A1 (en) | 2006-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1674941A (zh) | 固体纳米药物及其制备方法 | |
Campardelli et al. | Supercritical fluids applications in nanomedicine | |
Elgart et al. | Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds | |
Chaudhary et al. | Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review | |
CN100462066C (zh) | 药剂的新制剂及其制备和应用方法 | |
US6146663A (en) | Stabilized nanoparticles which may be filtered under sterile conditions | |
Patidar et al. | A review on novel lipid based nanocarriers | |
Vemula et al. | Solubility enhancement techniques | |
Jatwani et al. | An overview on solubility enhancement techniques for poorly soluble drugs and solid dispersion as an eminent strategic approach | |
Fuhrmann et al. | PEG nanocages as non-sheddable stabilizers for drug nanocrystals | |
US20100291200A1 (en) | Formulations for poorly soluble drugs | |
Kumar et al. | Novel approaches for enhancement of drug bioavailability | |
JP2000501989A (ja) | 無菌条件下にろ過可能な安定化されたナノ粒子 | |
Rupenagunta et al. | Solid lipid nanoparticles-A versatile carrier system | |
CN100479807C (zh) | 药物输送系统——固体纳米药物的制备方法 | |
Khafoor et al. | Recent progress in synthesis of nano based liposomal drug delivery systems: A glance to their medicinal applications | |
US20160287552A1 (en) | Drug delivery system comprising gelatine nano-particles for slowly releasing hardly-water soluble substances and its preparation method | |
WO2006034147A2 (en) | Compositions and methods for the preparation and administration of poorly water soluble drugs | |
Vadlamudi et al. | Disparate practical way of doing solubility enhancement study to improve the bioavailability of poorly soluble drugs | |
CN1502332A (zh) | 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法 | |
Khatri et al. | Solubility enhancement techniques: an overview | |
Patel et al. | Solubility enhancement technologies and research emerged | |
CN101579335A (zh) | 药剂的新制剂及其制备和应用方法 | |
Ain et al. | An overview on various approaches used for solubilization of poorly soluble drugs | |
Hapse et al. | Nanotechnology Based Approaches For Enhancements of Bioavailability of Sustain Release Formulation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1083749 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1083749 Country of ref document: HK |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Haikou Pharmaceutical Factory Co., Ltd. Assignor: Liu Yunqing|Liu Xiying|Liu Wei|Liu Tong Contract record no.: 2011110000010 Denomination of invention: Solid nano-medicine and preparing method thereof Granted publication date: 20090729 License type: Common License Open date: 20050928 Record date: 20110307 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090729 Termination date: 20190813 |
|
CF01 | Termination of patent right due to non-payment of annual fee |